Skip to Main Content

Paper Details

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
Ann Oncol
11
2020
Author NameAffiliation
Cora N SternbergEnglander Institute for Precision Medicine, Weill Cornell Medical Center
Fred SaadMontreal Cancer Institute, Montreal University Hospital Center (CHUM)
Maha HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine
  • 1 - 3

Datasets